Hear Insights From Medical Experts
Join medical experts for a conversation about PLUVICTO
Register for an event to:
Dive into PSMAfore efficacy and safety data for PLUVICTO in patients with mCRPC after only 1 ARPI1
Hear medical experts discuss mCRPC and PLUVICTO1
Learn more about PLUVICTO and getting patients started on a radioligand therapy1
ARPI, androgen receptor pathway inhibitor; mCRPC, metastatic castration-resistant prostate cancer.
Learn what medical experts have to say about PLUVICTO after only 1 ARPI1
Care Team Perspectives for a Patient With mCSPC Who Received an ARPI and Recently Progressed to mCRPC
Nuclear medicine physician Dr Phillip J. Koo, medical oncologist Dr Scott T. Tagawa, and urologist Dr Jason M. Hafron walk through the case of a patient who previously received an ARPI for mCSPC and recently progressed to mCRPC.
Medical Expert Perspectives on a Patient With mCRPC After Progression on an ARPI
Watch as nuclear medicine physician Dr Phillip J. Koo, medical oncologist Dr Scott T. Tagawa, and urologist Dr Jason M. Hafron discuss options for a patient with mCRPC who experienced progression after an ARPI.
Starting PLUVICTO – An Interview With Dr Finkelstein and Dr Pieczonka
Radiation oncologist Steven Finkelstein, MD, FACRO and Urologist Christopher Pieczonka, MD discuss the logistics and reimbursement of administering PLUVICTO to a patient with PSMA+ mCRPC after only 1 ARPI.
An Expert Interview: Use of PLUVICTO for mCRPC Before Chemotherapy
Watch radiation oncologist Steven Finkelstein, MD, FACRO, and Urologist Christopher Pieczonka talk about the first patient in the US to receive PLUVICTO in a commercial setting after approval of PLUVICTO prior to chemotherapy.
Expert Panel Perspectives on the Efficacy and Safety of PLUVICTO in PSMAfore
Watch expert panelists share insights on the PSMAfore trial, presenting the efficacy and safety data for PLUVICTO in patients with mCRPC.
Importance of Early Action in Care for Patients with mCRPC
Listen to three medical experts explore the importance of early, effective treatment for patients with mCRPC, review the role of PSMA PET imaging in patient selection, and explain how targeted radioligand therapies like PLUVICTO work.
Best Practices in Providing Treatment as a Multidisciplinary Team
Join a panel of 3 HCPs as they share best practices in patient management, communication between specialists, and key administration considerations for PLUVICTO, highlighting the value of a multidisciplinary approach across the mCRPC treatment journey.
mCSPC, metastatic castration-sensitive prostate cancer.
Learn what medical experts have to say about PLUVICTO after ARPI and chemo1
Prostate Cancer & PLUVICTO Overview
Join Gordon Brown, DO, Mark Fleming, MD, Glen Gejerman, MD, and Christina Fareri, LPN, as they discuss PLUVICTO, a treatment option for patients with PSMA+ mCRPC.
VISION Efficacy and Safety
Join Gordon Brown, DO, Mark Fleming, MD, Glen Gejerman, MD, and Christina Fareri, LPN, as they review the results of the VISION trial.
PLUVICTO Dosing & Administration
Join Gordon Brown, DO, Mark Fleming, MD, Glen Gejerman, MD, and Christina Fareri, LPN, as they dive into the dosing and administration of PLUVICTO.
Prostate Cancer, PSMA, and PLUVICTO
Watch Neal Shore, MD, FACS, provide an overview of the role of PSMA-PET, and the targeted therapy PLUVICTO, in mCRPC.
Prostate Cancer, PSMA, and PLUVICTO
Join Mark Fleming, MD, in discussing PSMA-PET imaging and PLUVICTO, including its mechanism of action in the mCRPC space.
VISION Study Design
Watch Mark Fleming, MD, provide an overview of the study design for VISION, a trial assessing PLUVICTO in patients with mCRPC.
VISION Study Design
Join Neal Shore, MD, FACS, as he walks you through the VISION trial study design.
PLUVICTO Patient Identification
Neal Shore, MD, FACS, discusses which types of patients may be eligible for PLUVICTO based on the VISION trial.
PLUVICTO Patient Identification
Mark Fleming, MD, reviews the patient population in the VISION trial and discusses which types of patients may be eligible for PLUVICTO.
PET, positron emission tomography; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.
Read the latest clinical perspectives on PLUVICTO
The Bullseye: The VISION Study
The first in a series of newsletters covering topics important to HCPs considering PLUVICTO for their patients.
The Bullseye: The PSMAfore Study In Review
The second in a series of newsletters covering topics important to HCPs considering PLUVICTO for their patients, with a focus on the PSMAfore study
The Bullseye: Third Edition
In the third installment in a series of newsletters, two medical experts describe their experience working with Novartis to provide PLUVICTO to patients and the use of PLUVICTO in patients with mCRPC, prior to chemotherapy.